Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVIGATE ESUS
2013-000768-27Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in embolic stroke of undetermined source (ESUS) comparing Rivaroxaban arm with Aspirin arm (2 arms). Primary endpoint: Time to first recurrent stroke or systemic embolism. Started Sep 2014; status: completed.
02
Drugs
rivaroxabanaspirin
03
Conditions
embolic stroke of undetermined source (ESUS)
Beyond the preview
Go deeper on 2013-000768-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000768-27.